Hilal Lashuel

photo placeholder image

Associate Professor in Neuroscience

hilal.lashuel@epfl.ch +41 21 69 39691 http://lashuel-lab.epfl.ch

Citizenship : USA

AI 2151 (Bâtiment AI)
Station 19
CH-1015 Lausanne

AI 2151 (Bâtiment AI)
Station 19
CH-1015 Lausanne

Administrative data


Teaching & PhD


  • Life Sciences Engineering,

PhD Programs

  • Doctoral Program in Biotechnology and Bioengineering
  • Doctoral Program in Neuroscience

PhD Students


Neuroscience: from molecular mechanisms to disease

The goal of the course is to guide students through the essential aspects of molecular neuroscience and neurodegenerative diseases. The student will gain the ability to dissect the molecular basis of disease in the nervous system in order to begin to unde... goto

Selected topics in life sciences

The course presents an overview on how recent advances at the interfaces of biology, biotechnology, engineering, physical sciences, and medicine are 1) shaping the landscape of biomedical research; 2) contributing to improving our quality of life and; 3) ... goto


Mission and Research Interest

Our Mission: To elucidate the molecular mechanisms underlying neurodegeneration in Alzheimer's and Parkinson's disease and develop novel strategies to facilitate the diagnosis, prevention and treatment of these diseases.

Our Research Goals 1. Elucidation of the relationship between the processes of protein misfolding and aggregation and neurodegeneration in Alzheimer’s disease (AD), Parkinson’s disease (PD) and related neurodegenerative disorders. 2. To understand the molecular mechanisms through which disease-associated variants and post-translational modification of the gene products associated with AD and PD induce neuronal dysfunction and neurodegeneration. 3. Develop novel therapeutic strategies based on modulating protein aggregation and clearance.

Research interest: Current research in the Lashuel laboratory focuses on applying chemical, biophysical, structural and molecular biology approaches to understanding the molecular and structural basis of protein misfolding and self-assembly and the mechanisms by which these processes contribute to the physiological and pathogenic properties of specific proteins implicated in neurodegenerative diseases. Current research efforts cover the following topics: (1) Elucidating the molecular and cellular determinants underlying amyloid-? and ?-synuclein aggregation and toxicity in Alzheimer’s diseases and Parkinson’s disease and related disorders. (2) Elucidating the structural basis of amyloid-associated toxicity by correlating the structural properties of defined aggregates in the amyloid pathway to their toxicity in primary neuronal cultures; (3) Developing innovative chemical approaches and novel tools to monitor and control protein folding/misfolding and self-assembly in vitro and in vivo with spatial and temporal resolution; (4) Understanding the role of post-translational modifications in the pathogenesis of neurodegenerative diseases; (5) Identifying and validating new therapeutic targets for treating Parkinson’s disease; (6) Developing novel therapeutic strategies to treat neurodegenerative diseases based on modulation of protein aggregation and clearance.

Research in the Lashuel lab is funded by several international funding agencies and foundations, including the Swiss National Science Foundation, European FP7 program (Marie Curie and ERC grants), Human Science Frontiers, Strauss Foundation, Cure the Huntington’s disease foundation and Michael J Fox foundation and is supported by collaborations with pharmaceutical and biotech companies (http://lashuel-lab.epfl.ch/page-50538-en.html), Nestle, Merck-Serono, AC Immune and Johnson and Johnson.